Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Claire Dees"'
Autor:
Benjamin Vincent, Dominic Moore, Mark Woodcock, Carey Anders, Amanda Van Swearingen, Maria Sambade, Luz Cuaboy, Amy Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin Calhoun, Lisa Carey, Claire Dees, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Jonathan Serody
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/66ceae14360c4fa2897157a5c2f6fcac
Autor:
Yuan Yuan, Michael Klichinsky, Saar Gill, Melissa Johnson, Thomas Condamine, Jennifer Specht, Richard T Maziarz, Kim Reiss, Debora Barton, Daniel Cushing, Joanne Mortimer, Paula R Pohlmann, E Claire Dees, Naoto Ueno, Mathew Angelos, Ramona F Swaby, Yara Abdou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ac9f82ba4b6e4214881cf6857a725f08
Autor:
Zev M. Nakamura, Allison M. Deal, Eliza M. Park, Kate E. Stanton, Yesy E. Lopez, Laura J. Quillen, Erin O’Hare Kelly, Hillary M. Heiling, Kirsten A. Nyrop, Emily M. Ray, E. Claire Dees, Katherine E. Reeder‐Hayes, Trevor A. Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Julia K. Rauch, Ranjit Joseph, Anureet Copeland, Megan A. McNamara, Tim A. Ahles, Hyman B. Muss
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8172-8183 (2023)
Abstract Background Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in these patients. This trial examined the feasibility, tolerability, acceptability, a
Externí odkaz:
https://doaj.org/article/d2562d0fa30245228e0ed1a363d25b5d
Autor:
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc R. Matrana, Mark E. Burkard, Eddy Shih-Hsin Yang, William Jeffery Edenfield, E. Claire Dees, Adedayo A. Onitilo, Michael Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon C. Hwang, J. Marie Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory Masters, Sachdev Thomas, Malek Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Tomlins et al. develop an Immunotherapy Response Score (IRS) to predict clinical benefit from checkpoint inhibition across solid tumors. IRS integrates TMB and gene expression, is evaluable from FFPE material, and is predictive for real-world progres
Externí odkaz:
https://doaj.org/article/4592ab4c5780454fabd8956daa3f8f79
Autor:
Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemothera
Externí odkaz:
https://doaj.org/article/d2b06f8f41a040519a09fe040f35b01e
Autor:
Natalia Mitin, Kirsten A. Nyrop, Susan L. Strum, Anne Knecht, Lisa A. Carey, Katherine E. Reeder-Hayes, E. Claire Dees, Trevor A. Jolly, Gretchen G. Kimmick, Meghan S. Karuturi, Raquel E. Reinbolt, JoEllen C. Speca, Erin A. O’Hare, Hyman B. Muss
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and detrimental effect on quality of life. We determined if the expression of p16, a biomar
Externí odkaz:
https://doaj.org/article/3bdd56b0e4984dc1bac5b5e36a777518
Autor:
Robert Wesolowski, Hope Rugo, Erica Stringer-Reasor, Hyo S. Han, Jennifer M. Specht, E. Claire Dees, Peter Kabos, Ulka Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander I. Spira, Anne F. Schott, Maysa Abu-Khalaf, Pratima Nayak, Brian F. Sullivan, Igor Gorbatchevsky, AND Rachel M. Layman
Publikováno v:
Cancer Research. 83:PD13-05
Background: Addition of PI3K/mTOR inhibitor after progression on CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) can potentially restore sensitivity to CDK4/6i and prevent adaptive activation of the PI3K/mTOR pathway. To evaluate this hypothesi
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer
Autor:
Danielle M. File, Tomas Pascual, Allison M. Deal, Amy Wheless, Charles M. Perou, E. Claire Dees, Lisa A. Carey
Publikováno v:
Breast Cancer Res Treat
PURPOSE: This study evaluated whether patients with de novo metastatic breast cancer (MBC) have superior outcomes compared to those with recurrent MBC in a contemporary treatment era and examined factors related to outcome differentials. METHODS: Usi
Autor:
Benjamin G. Vincent, Danielle M. File, Karen P. McKinnon, Dominic T. Moore, Jeffrey A. Frelinger, Edward J. Collins, Joseph G. Ibrahim, Lisa Bixby, Shannon Reisdorf, Sonia J. Laurie, Yara A. Park, Carey K. Anders, Frances A. Collichio, Hyman B. Muss, Lisa A. Carey, Hendrik W. van Deventer, E. Claire Dees, Jonathan S. Serody
Publikováno v:
J Immunol
Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors.Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58210558b93cf8d4ce8c9aff837b458
https://doi.org/10.1158/1078-0432.c.6524799
https://doi.org/10.1158/1078-0432.c.6524799